Abivax SA’s U.S.-listed ADS (ABVX) traded lower Monday (April 13, 2026), down roughly 3.10% to $123.36, in what appears to be a positioning-driven pullback rather than a headline-driven selloff. Recent company communications have centered on a major upcoming catalyst—topline results from the Phase 3 ABTECT-UC maintenance trial of obefazimod expected in late Q2 2026—making the stock particularly sensitive to risk-on/risk-off swings as the readout window approaches. (ir.abivax.com)

Abivax is advancing obefazimod for moderate-to-severely active ulcerative colitis, with the ongoing Phase 3 maintenance trial flagged as a key 2026 inflection point. In its March 23, 2026 update, the company reiterated it remains on track for late-Q2 2026 maintenance topline results, with broader regulatory preparation efforts discussed in earlier corporate outlook communications. (ir.abivax.com)

For late-stage clinical biotechs, stocks often drift and swing as traders adjust exposure into binary events, especially after large prior gains and heavy catalyst focus. In the absence of a new filing, trial update, or regulatory decision today, the most likely drivers are profit-taking, technical selling, and hedging activity around the late-Q2 data window rather than a change to the underlying trial timeline. (ir.abivax.com)